# A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)

Source: https://onco.cc/trials/nct06616636/  
OnCo record `nct06616636` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Rezatapopt run by M.D. Anderson Cancer Center, now recruiting.

## Summary

A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome) is a phase 1 interventional study registered as NCT06616636 by M.D. Anderson Cancer Center, with 24 participants planned, started 2025-01-30, primary completion expected 2027-08-27. Conditions recorded: Myelodysplastic Syndrome, Acute Myeloid Leukemia. Interventions recorded: Azacitidine, Rezatapopt.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06616636
- Phase: 1
- Setting: A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
- Sponsor: M.D. Anderson Cancer Center
- Enrolled: 24

## Sources

- ClinicalTrials.gov NCT06616636: https://clinicaltrials.gov/study/NCT06616636

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- drugs: [Rezatapopt](https://onco.cc/drugs/rezatapopt/)
- companies: [PMV Pharma](https://onco.cc/companies/pmv-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct06616636.json